Traders, investors and Star Wars fans alike must be thrilled with Walt Disney Co (DIS, $110.57) these days. As well they should.
In successive days, Disney announced a deal to acquire a large part of 21st Century Fox (FOXA) and debuted the latest installment of the Star Wars saga in a wide release. Whether Star Wars: The Last Jedi can eclipse the $2 billion mark like 2015s Star Wars: The Force Awakens did (and even beat Episode VII outright) remains to be seen, but its dramatic acquisition of Fox is unquestionably a blockbuster.
Disney stock is trading at a discount to the broader market and sits within reach of its all-time high of $122.08 hit more than two years ago. The blue chip looks like a buy on the heels of this news.
Disney the Streaming Giant?
Disney is spending $52.4 billion to acquire Foxs movie and televisions studios, cable and international TV businesses, local sports channels and some other assets.
Top 5 Blue Chip Stocks To Own Right Now: ZELTIQ Aesthetics, Inc.(ZLTQ)
- [By James E. Brumley]
This week, Botox maker Allergan plc (NYSE:AGN) shelled out $2.5 billion for body-sculpting outfit Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). The pairing is a nice opportunity for both organizations to cross-sell to one another’s customers. Allergan’s Botox customers seeking a more youthful face will also likely want the better body Zeltiq Aesthetics provides, and Zeltiq Aesthetics’ customers are natural candidates for Botox injections that Allergan facilitates.
The acquisition, though, is just a microcosm of a bigger trend that’s still picking up steam. That trend is, as the industry’s capabilities to restore youth, slim waists, whiten teeth, improve skin, and nip and tuck here and there improve with science, demand for these increasingly effective ‘tweaks’ is soaring. Names like the aforementioned Allergan, Cynosure, Inc. (NASDAQ:CYNO), Zeltiq Aesthetics and Align Technology, Inc. (NASDAQ:ALGN) are all driving impressive growth. And, they’re all looking to expand their footprint in front of the rising tide.
Not every name riding this growth wave is going to be a large cap stock or a household name though. There’s a small cap stock called RepliCel Life Sciences (OTCMKTS:REPCF, CVE:RP) that could soon be turning a lot of heads not just of investors, but of potential suitors.
In simplest terms, RepliCel Life Sciences has two key sciences that serve as the foundation for three therapies and one medical device.
The first of the two biological premises is based on the company’s non-bulbar dermal sheath fibroblast platform, and currently includes treatments for chronic tendinosis and skin aging. The second is the company’s dermal sheath cup (DSC) cell platform for the treatment of androgenetic alopecia (pattern baldness).
The three marketable products those two sciences are driving are RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair regeneration. The device is a dermal injector – currently categorized as R
Top 5 Blue Chip Stocks To Own Right Now: KeyCorp(KEY)
- [By Craig Jones]
On CNBC's Fast Money Halftime Report, Jon Najarian said he noticed big options volume in the December weekly, 18 strike calls in KeyCorp (NYSE: KEY). He decided to follow the trade and he is going to hold the position for 1 to 2 days.
- [By WWW.THESTREET.COM]
But then there was good news from rail transport company CSX (CSX ) , which saw growth in every one of its business lines. Foot Locker (FL) also surprised to the upside, sending shares up a quick 5.3%. Cramer fave and Action Alerts PLUS holding KeyCorp (KEY) also delivered, as did paint maker Sherwin-Williams (SHW) .
- [By WWW.THESTREET.COM]
On the show’s “Lightning Round” segment, Jim Cramer as bullish on Penn National Gaming (PENN) , KeyCorp (KEY) and TherapeuticsMD (TXMD) .
Top 5 Blue Chip Stocks To Own Right Now: ANSYS, Inc.(ANSS)
- [By Shane Hupp]
Ansys (NASDAQ:ANSS) Director James E. Cashman III sold 862 shares of the firm’s stock in a transaction on Tuesday, April 10th. The stock was sold at an average price of $158.00, for a total value of $136,196.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
- [By Lisa Levin]
Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Wednesday's regular session.
Top 5 Blue Chip Stocks To Own Right Now: Euro/Yen(EJ)
- [By Belinda Cao]
E-House China Holdings Ltd. (EJ), a real estate brokerage, gained 9.2 percent to $9.70, extending it advance to a third week. Its American depositary receipts retreated 3.1 percent Sept. 20 from the highest level since May 2011.
Top 5 Blue Chip Stocks To Own Right Now: MINDBODY, Inc.(MB)
- [By Peter Graham]
Small cap online wellness services stock MINDBODY Inc (NASDAQ: MB) reportedQ2 2017 earnings after the market closed Wednesday with results beating expectations. Total revenue was up 31% to $44.1 million as subscription and services revenue rose 29% to $26.0 million and payments revenue rose 37% to $17.6 million. End of period subscribers increased 6% year over year to 59,345, end of period High Value Subscribers increased 13% year over year, average monthly revenue per subscriber (ARPS) grew 21% year over year to approximately $244 and payments volume increased 22% year over year to over $1.9 billion. The GAAP net losswas $4.4 million versus a GAAP net loss of $6.6 million. Rick Stollmeyer, Co-founder and CEO of MINDBODY, commented:
- [By Joe Tenebruso]
Mindbody (NASDAQ:MB) provides cloud-based software solutions to the health and wellness industry: Think spas, yoga studios, and fitness classes. It’s a massive market that’s gone largely underserved — and Mindbody is working to address that need.
- [By Chris Lange]
MindBody, Inc. (NASDAQ: MB) reported its fourth quarter results after the markets closed on Wednesday. The company said that it had $0.03 in EPS on $49.7 million in revenue. The consensus estimates were looking for $0.01 in EPS and $48.9 million in revenue. Analysts had this to say about MindBody after earnings: